GelMA Cell-Laden Hydrogels for Faster Crosslinking and Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved GelMA polymer compositions that are more cost-effective, easier to produce, and provide better biocompatibility, faster crosslinking, stronger adhesion, controlled release of therapeutic agents, and higher cell viability for treating soft tissue injuries and diseases.
Innovation Solution
The development of polymer compositions comprising chemically modified gelatin, such as GelMA, with specific molecular weights and degrees of methacrylation, combined with crosslinking initiators and optional hydrophilic surfactants, which are photocrosslinked to form hydrogels for application in soft tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional GelMA polymer compositions are used, then therapeutic delivery to soft tissues is achieved, but production costs are high and manufacturing complexity is increased
Solution Approach 1:
The patent modifies the chemical parameters of gelatin by controlling the degree of methacrylation (5-40%) and molecular weight (75-180 kDa), which simplifies the overall manufacturing process while maintaining therapeutic effectiveness. This parameter optimization reduces production costs and complexity.
Solution Approach 2:
The invention creates composite polymer compositions by combining chemically modified gelatin with crosslinking initiators and therapeutic agents. This composite approach enables simplified one-step photocrosslinking manufacturing while achieving multiple functional objectives simultaneously.
2Strength
If conventional GelMA compositions are used, then therapeutic delivery is achieved, but crosslinking speed and strength are insufficient
Solution Approach 1:
The patent optimizes the degree of methacrylation parameter to enhance crosslinking reactivity. By adjusting this chemical parameter within specific ranges (5-40%), the composition achieves faster crosslinking kinetics and stronger final crosslinking strength, reducing the time required for effective tissue repair.
Solution Approach 2:
The invention replaces slow, traditional chemical crosslinking mechanisms with photo-initiated crosslinking. This substitution enables rapid, controlled crosslinking upon light exposure, significantly reducing crosslinking time while achieving superior crosslinking strength.
3Reliability
If conventional GelMA compositions are used, then therapeutic delivery is achieved, but biocompatibility and cell viability are suboptimal
Solution Approach 1:
The patent carefully controls the degree of methacrylation (5-40%) and molecular weight (75-180 kDa) parameters to optimize biocompatibility. These parameter adjustments ensure that the polymer maintains appropriate degradation rates and cellular interactions, minimizing toxicity while maximizing therapeutic benefit.
Solution Approach 2:
The invention creates local quality variations within the polymer composition by incorporating specific functional groups and crosslinking densities. This allows different regions of the hydrogel to exhibit optimized properties for cell adhesion, proliferation, and differentiation, enhancing overall biocompatibility.
4Strength
If conventional GelMA compositions are used, then therapeutic delivery is achieved, but adhesion strength to target tissue is insufficient
Solution Approach 1:
The patent creates composite formulations that integrate adhesion-promoting functional groups within the chemically modified gelatin structure. This composite approach achieves strong tissue adhesion without requiring separate adhesion layers or complex multi-step manufacturing processes.
Solution Approach 2:
The invention designs the chemically modified gelatin to perform multiple functions simultaneously: structural framework formation, crosslinking, and tissue adhesion. This multi-functionality simplifies manufacturing while achieving strong, reliable adhesion to target soft tissues.
5Duration of action of moving object
If conventional GelMA compositions are used, then therapeutic delivery is achieved, but controlled release of therapeutic agents is limited
Solution Approach 1:
The patent utilizes parameter changes in the polymer network structure (crosslinking density, mesh size, degradation rate) to control therapeutic agent release kinetics. By adjusting these parameters, the system achieves sustained, controlled release over extended periods without requiring complex release mechanisms.
Solution Approach 2:
The invention enables the hydrogel to self-regulate therapeutic agent release through its inherent degradation and swelling properties. The polymer network automatically controls release rates based on local environmental conditions (pH, enzyme presence), eliminating the need for external control systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions offer lower production costs, improved biocompatibility, faster and stronger crosslinking, controlled release of therapeutic agents, and enhanced cell viability, making them suitable for treating ocular defects and diseases like corneal ulcers and retinal degeneration.
Implementation Method 1
the polymer composition comprises: (i) at least one chemically modified gelatin (optionally an acrylated gelatin, such as GelMA); (ii) at least one polymer crosslinking initiator; and (iii) at least one therapeutic agent (e.g., a cell)
Data Source
AI summary
The present disclosure provides improved polymer compositions, such as GelMA polymer compositions. In certain embodiments, the improved polymer compositions can be used for delivering one or more therapeutic agents, such as cells, to a target therapeutic area, such as the eye of a subject. In certain embodiments, the improved polymer compositions are hydrogels which comprises gelatin methacryloyl (i.e., GelMA) or polymerically crosslinked derivatives thereof.